LITTLE KNOWN FACTS ABOUT AFATINIB.

In 2010, Ariad announced final result from a section I research of ponatinib in individuals with resistant and refractory Serious myeloid leukemia and Philadelphia-favourable acute lymphoblastic leukemia (Ph+ ALL).Liver complications warning: Afatinib can cause or worsen liver complications. Your health care provider will very likely do blood exams